"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 2 | 1 | 3 |
| 2001 | 3 | 3 | 6 |
| 2002 | 3 | 4 | 7 |
| 2003 | 0 | 3 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 5 | 8 | 13 |
| 2006 | 2 | 2 | 4 |
| 2007 | 3 | 5 | 8 |
| 2008 | 3 | 1 | 4 |
| 2009 | 4 | 1 | 5 |
| 2010 | 5 | 8 | 13 |
| 2011 | 6 | 2 | 8 |
| 2012 | 4 | 2 | 6 |
| 2013 | 6 | 2 | 8 |
| 2014 | 4 | 3 | 7 |
| 2015 | 4 | 5 | 9 |
| 2016 | 2 | 2 | 4 |
| 2017 | 6 | 4 | 10 |
| 2018 | 5 | 2 | 7 |
| 2019 | 2 | 4 | 6 |
| 2020 | 5 | 9 | 14 |
| 2021 | 5 | 3 | 8 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 3 | 4 |
| 2024 | 4 | 2 | 6 |
| 2025 | 4 | 3 | 7 |
| 2026 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. Cancer Treat Rev. 2022 Sep; 109:102429.
-
Cancer/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol. 2021 11; 76:218-231.
-
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021 01 04; 131(1).
-
Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11).
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
-
Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019 08 23; 18(1):128.
-
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018 04 05; 3(7).
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
-
Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer. Proteomics Clin Appl. 2017 09; 11(9-10).
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.